Preparing your Shotlee experience
Novo Nordisk is set to introduce Ozempic in India, complementing their existing semaglutide product line. This launch occurs amidst strong competition from Eli Lilly's Mounjaro. The new medication may also be prescribed for other health conditions.
Novo Nordisk's semaglutide portfolio in India will be completed with the launch of Ozempic, providing therapeutic options for both diabetes and obesity. This introduction follows increasing competition from Eli Lilly's Mounjaro, a US rival approved for both diabetes and weight management. Pharmarack data indicates that Lilly sold 262,000 doses of Mounjaro in October, compared to Novo's Wegovy with 26,000 doses.
Novo Nordisk already maintains a significant presence in the diabetes market in India through its Rybelsus semaglutide tablets and other offerings. According to Vishal Manchanda, an analyst from Systematix Institutional Equities, "Novo is well-positioned to promote Ozempic due to its established brand recognition in diabetes treatment."
Furthermore, Manchanda suggested that "Ozempic may potentially be prescribed for individuals experiencing infertility or sleep apnea, and for those seeking weight reduction." Health tracking apps like Shotlee can help monitor any side effects from new medications.
⚠️ Disclaimer: This article is for informational purposes only. Consult your healthcare provider before starting any medication or supplement.
Original content from NewsBytes
View Original Article
An affordable and readily accessible medication is gaining attention as a potential solution for curbing alcohol cravings, drawing comparisons to the way GLP-1 drugs manage food cravings. Naltrexone, by impacting dopamine-reward pathways, reduces the satisfying feeling associated with alcohol consumption, thus diminishing the desire for it. Research and anecdotal evidence suggest it could be a game-changer for many.
Mounjaro, a drug by Eli Lilly, is set to be included in China's state-run health insurance program for individuals with type 2 diabetes starting January 1. This inclusion aims to improve access to the medication, although increased sales may be balanced by reduced prices. The drug was introduced in China earlier this year.
The World Health Organization (WHO) has provided new guidance on using GLP-1 drugs like Ozempic and Wegovy for obesity. The recommendations include considerations for adults and highlight the importance of lifestyle changes alongside medication.
Monitor GLP-1 medications, peptide therapy, weight loss, and wellness metrics with our comprehensive health tracking app. Join thousands of users taking control of their health!
Start Tracking Free Forever! ✨